In the present study, we showed that fenofibrate treatment increased hepatic steatosis and the liver triglyceride content through the up-regulation of mature SREBP-1c (a key lipogenic transcription factor) expression via the direct binding of PPARα to the DR1 motif of the SREBP-1c gene [15]. The gene discussed is SREBF1; the disease is fatty liver disease.